What type of drug is eltrombopag?
Eltrombopag is in a class of medications called thrombopoietin receptor agonists. It works by causing the cells in the bone marrow to produce more platelets.
Is eltrombopag generic?
Eltrombopag is the generic name for the trade name drug Promacta. In some cases, health care professionals may use the trade name, Promacta, when referring to the generic drug name, eltrombopag.
Is eltrombopag a chemotherapy drug?
Eltrombopag (Promacta) is an FDA approved drug for the treatment of chronic idiopathic thrombocytopenic purpura (ITP)- a condition of having an abnormally low platelet count….Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia.
Last Update Posted: | April 2, 2014 |
Last Verified: | April 2013 |
Is eltrombopag safe in pregnancy?
Eltrombopag has been assigned to pregnancy category C by the Food and Drug Administration (FDA). There are no adequate and well-controlled studies of eltrombopag use in pregnancy. Eltrombopag should be used in pregnancy only when benefit outweighs risk.
How long can you take eltrombopag?
Eltrombopag is usually taken for 6 months. It may take up to 4 weeks before the medicine prevents major bleeding episodes. Keep taking eltrombopag as directed and tell your doctor if you have any bruising or bleeding episodes after 4 weeks of taking eltrombopag.
How long can you take eltrombopag for?
What is another name for eltrombopag?
Brand name: Promacta. Eltrombopag oral tablet is used to treat low platelet levels due to chronic immune thrombocytopenia (ITP) or chronic hepatitis C virus infection.
Can you take promacta while pregnant?
Eltrombopag should be used during pregnancy only if the benefit outweighs the risk. Risk Summary: Insufficient data exists to assess any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.
How long does it take for eltrombopag to work?
It may take up to 2 weeks for patients to respond to eltrombopag.
Is eltrombopag an immunosuppressant?
We added eltrombopag, a thrombopoietin-receptor agonist, to standard immunosuppressive therapy in patients with previously untreated severe aplastic anemia.